Details for New Drug Application (NDA): 218912
✉ Email this page to a colleague
NDA 218912 describes PROCHLORPERAZINE MALEATE, which is a drug marketed by Ajanta Pharma Ltd, Amneal, Aurobindo Pharma Ltd, Bionpharma, Chartwell Rx, Dr Reddys Labs Sa, Duramed Pharms Barr, Glenmark Pharms Ltd, Ivax Sub Teva Pharms, Leading, Novitium Pharma, Pharmobedient, Teva Pharms, and Zydus Lifesciences, and is included in seventeen NDAs. It is available from twenty suppliers. Additional details are available on the PROCHLORPERAZINE MALEATE profile page.
The generic ingredient in PROCHLORPERAZINE MALEATE is prochlorperazine maleate. There are twenty-one drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the prochlorperazine maleate profile page.
The generic ingredient in PROCHLORPERAZINE MALEATE is prochlorperazine maleate. There are twenty-one drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the prochlorperazine maleate profile page.
Summary for 218912
| Tradename: | PROCHLORPERAZINE MALEATE |
| Applicant: | Leading |
| Ingredient: | prochlorperazine maleate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 218912
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| PROCHLORPERAZINE MALEATE | prochlorperazine maleate | TABLET;ORAL | 218912 | ANDA | Leading Pharma, LLC | 69315-265 | 69315-265-01 | 100 TABLET, FILM COATED in 1 BOTTLE (69315-265-01) |
| PROCHLORPERAZINE MALEATE | prochlorperazine maleate | TABLET;ORAL | 218912 | ANDA | Leading Pharma, LLC | 69315-266 | 69315-266-01 | 100 TABLET, FILM COATED in 1 BOTTLE (69315-266-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 5MG BASE | ||||
| Approval Date: | Sep 30, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 10MG BASE | ||||
| Approval Date: | Sep 30, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
